435 related articles for article (PubMed ID: 29806344)
1. [Effect of lipopolysaccharide on osteoclasts formation and bone resorption function and its mechanism].
Zeng L; Xu Y; Xing G
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2018 May; 32(5):568-574. PubMed ID: 29806344
[TBL] [Abstract][Full Text] [Related]
2. Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice.
Hayashi S; Tsuneto M; Yamada T; Nose M; Yoshino M; Shultz LD; Yamazaki H
Endocrinology; 2004 Jun; 145(6):2721-9. PubMed ID: 14988381
[TBL] [Abstract][Full Text] [Related]
3. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
4. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro.
Chai L; Zhou K; Wang S; Zhang H; Fan N; Li J; Tan X; Hu L; Fan X
Cell Physiol Biochem; 2018; 48(5):2123-2133. PubMed ID: 30110702
[TBL] [Abstract][Full Text] [Related]
5. [Experimental study on the inhibition of Formononetin on the differentiation of osteoclasts induced by RANKL].
Hong YB; Jiang H; Wang JW; Yu PF; You WL
Zhongguo Gu Shang; 2020 Jan; 33(1):64-70. PubMed ID: 32115927
[TBL] [Abstract][Full Text] [Related]
6. Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro.
Yamaguchi M; Uchiyama S
Int J Mol Med; 2004 Jul; 14(1):81-5. PubMed ID: 15202020
[TBL] [Abstract][Full Text] [Related]
7. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
[TBL] [Abstract][Full Text] [Related]
8. Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro.
Wang L; Zhao R; Shi X; Wei T; Halloran BP; Clark DJ; Jacobs CR; Kingery WS
Bone; 2009 Aug; 45(2):309-20. PubMed ID: 19379851
[TBL] [Abstract][Full Text] [Related]
9. Thioacetamide promotes osteoclast transformation of bone marrow macrophages by influencing PI3K/AKT pathways.
Jin X; Li Y; Yang Y; Shen H; Chen J; Xu B; Xu J
J Orthop Surg Res; 2022 Jan; 17(1):53. PubMed ID: 35093114
[TBL] [Abstract][Full Text] [Related]
10. Arecoline suppresses RANKL-induced osteoclast differentiation in vitro and attenuates LPS-induced bone loss in vivo.
Liu FL; Chen CL; Lai CC; Lee CC; Chang DM
Phytomedicine; 2020 Apr; 69():153195. PubMed ID: 32200293
[TBL] [Abstract][Full Text] [Related]
11. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
12. [Effects of M-CSF concentration, RANKL concentration and M-CSF preinduction on osteoclastogenesis].
Dong W; Yu J; Qi M; Bai Y; Liang R; Chen H
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Dec; 27(6):1336-40. PubMed ID: 21374990
[TBL] [Abstract][Full Text] [Related]
13. [PROMOTION EFFECT OF FTY-720P ON TREATMENT OF BONE DEFECT WITH ALLOGRAFT BONE BY SUPPRESSING OSTEOCLAST FORMATION AND FUNCTION].
Huang Y; Huang D; Zhang D; Mou Y; Liu X
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2016 Apr; 30(4):426-31. PubMed ID: 27411269
[TBL] [Abstract][Full Text] [Related]
14. The generation of highly enriched osteoclast-lineage cell populations.
Quinn JM; Whitty GA; Byrne RJ; Gillespie MT; Hamilton JA
Bone; 2002 Jan; 30(1):164-70. PubMed ID: 11792580
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors.
Strålberg F; Kassem A; Kasprzykowski F; Abrahamson M; Grubb A; Lindholm C; Lerner UH
J Leukoc Biol; 2017 May; 101(5):1233-1243. PubMed ID: 28196851
[TBL] [Abstract][Full Text] [Related]
18. Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo.
Chen X; Chen X; Zhou Z; Mao Y; Wang Y; Ma Z; Xu W; Qin A; Zhang S
Exp Cell Res; 2019 Sep; 382(1):111470. PubMed ID: 31211955
[TBL] [Abstract][Full Text] [Related]
19. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
20. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]